Apoptosis signaling is regulated and executed by specialized proteins that often carry protein/protein interaction domains. One of these domains is the death effector domain (DED) that is predominantly found in components of the death-inducing signaling complex, which forms at the members of the death receptor family following their ligation. Both proapoptotic-and antiapoptotic-DEDcontaining proteins have been identified, which makes these proteins exquisitely suited to the regulation of apoptosis. Aside from their pivotal role in the control of the apoptotic program, DED-containing proteins have recently been demonstrated to exert their influence on other cellular processes as well, including cell proliferation. These data highlight the multiple roles for the members of this family, suggesting that they are suited to control both life and death decisions of cells. Additionally, because they can act proapoptotically, antiapoptotically, or in the regulation of the cell cycle, this family of proteins may be excellent candidates for cancer therapy targets.
Introduction
To ensure a coordinated execution of apoptosis, a number of specialized proteins have evolved. Many of these proteins are modular in structure with domains that regulate specific protein/protein interactions. In the classical caspase-dependent apoptosis pathway, a number of proteins contain such homotypic protein interaction domains. Four domains that mediate apoptotic signaling, the death effector domain (DED), the death domain (DD), the caspase activation and recruitment domain (CARD) and the pyrin domain (Fairbrother et al., 2001) , have been described. From the structure of the FADD DED (Eberstadt et al., 1998) , caspase-9 and Apaf-1 CARDs (Qin et al., 1999; Vaughn et al., 1999; Zhou et al., 1999) and the TNF-RI and CD95 DDs (Huang et al., 1996; Telliez et al., 2000) , it has become clear that these domains are structurally related and are comprised of a six a-helical structure. This review will focus on the function of cellular DED proteins. Viral proteins carrying DEDs have also been reported, and we refer the reader to some recent reviews on the subject (Krueger et al., 2001a; Derfuss and Meinl, 2002) .
FADD
Fas associated with a death domain (FADD) or MORT1 is a cytosolic adaptor protein that is critical for apoptotic signaling by CD95 (APO-1/Fas) and certain other death receptors of the TNFR1 family (Yeh et al., 1998) . The human and mouse FADD genes were identified and cloned from cDNA expression libraries in yeast-two-hybrid screens designed to identify cytosolic components of the CD95 signaling complex (Boldin et al., 1995; Chinnaiyan et al., 1995; Zhang and Winoto, 1996) . Two-dimensional gel analysis of the constituent molecules of the activated receptor complex confirmed an endogenous association of FADD with CD95 and its role as an intermediate in recruiting caspase-8 (Kischkel et al., 1995; Chinnaiyan et al., 1996a) . Human FADD is a 208 amino-acid protein encoded by two exons located on chromosome 11q13.3, a region amplified in certain breast adenocarcinomas . FADD has two well-characterized functional domains, an N-terminal DED and a C-terminal DD (Figure 1) , as well as a single phosphorylation site in a serine-rich region at its C-terminus, which has been proposed as a putative third-functional domain (Scaffidi et al., 2000) . The FADD DD is comprised of 80 amino acids containing six antiparallel amphipathic a-helices, a structure mimicked in the CD95 DD and necessary for the interaction of the two proteins (Boldin et al., 1995; Chinnaiyan et al., 1995; Jeong et al., 1999) . The DD of FADD also mediates its recruitment to the activated complexes of TNF-R1 through its association with TRADD, as well as to DR3 and TRAIL receptors 1 (DR4) and 2 (DR5) (Hsu et al., 1996; Chinnaiyan et al., 1996b; Chaudhary et al., 1997 ). FADD's N-terminus contains its DED, through which it interacts with one of the two DEDs of caspase-8, resulting in the recruitment of caspase-8 to the death-inducing signaling complex (DISC) (Boldin et al., 1996; Muzio et al., 1996) . Expression of a DED deletion mutant containing only the C-terminus of FADD (FADD-DN) functions as a dominant negative in death receptor-mediated apoptotic signaling because of its association with the activated receptor and its inability to recruit caspase-8 (Chinnaiyan et al., 1996a) . Conversely, overexpression of full-length FADD is proapoptotic, due to the inherent ability of the DED to oligomerize and form a complex that functionally resembles an activated receptor (Boldin et al., 1995; Chinnaiyan et al., 1995; Siegel et al., 1998) . This has prompted gene therapy studies that use FADD as a 'suicide gene' when targeted to tumor cells, resulting in the apoptosis of FADDpositive cells and regression of tumor volume in mice (Fan et al., 1999; Koga et al., 2001; Komata et al., 2001) . Another potential strategy is to sensitize tumors cells with low or undetectable levels of CD95 that are otherwise resistant to CD95-mediated apoptosis, increasing the effectiveness of the apoptotic signal when FADD is overexpressed (Kondo et al., 1998) .
FADD is selectively phosphorylated on a single amino acid at its C-terminus, serine 194. Although the exact stimulus that induces FADD phosphorylation remains unknown, it appears to be regulated in a cell cycle-dependent manner. FADD is predominantly found in the phosphorylated form in G2/M and in the unphosphorylated form in the G1 stage of the cell cycle (Scaffidi et al., 2000) . FADD phosphorylation does not appear to be involved in death signaling since both phosphorylated and unphosphorylated FADD are recruited to the DISC and a phosphorylation deletion mutant can functionally reconstitute CD95-mediated apoptotic signaling in FADD-deficient Jurkat cells (Kischkel et al., 1995; Zhang and Winoto, 1996; Scaffidi et al., 2000) . However, the phosphorylation site is conserved in mouse and rat FADD, and similarly phosphorylated in mouse FADD, suggesting that phosphorylation may be involved in a second function that is independent of death receptor signaling. Recently, it was shown that T cells from FADD null mice expressing FADD with the phosphorylation site (murine serine 191) replaced with aspartic acid have a very similar phenotype to T cells lacking FADD completely (Hua et al., 2003) , suggesting that the phosphorylation of FADD regulates its role in cell cycle progression. Our recent data also support the role of the FADD phosphorylation in cell cycle progression, as we recently found that the cell cycle block that is caused by overexpression of FADD-DN in the nontumor cell line MCF10A depends on an intact serine 194 phosphorylation site (unpublished data). These recent data suggest that the regulation of cell cycle progression by FADD in both lymphoid and nonlymphoid cells is regulated by the kinase that phosphorylates serine 194.
FADD null mice die in utero at E11.5, showing signs of cardiac failure and abdominal hemorrhaging, suggesting a role for FADD in embryonic development (Yeh et al., 1998) . Furthermore, several studies in mice with deficient FADD function have suggested a second role for FADD in cell growth and proliferation (Strasser and Newton, 1999) . Mice with FADD À/À T cells as well as mice expressing a dominant-negative transgene show reduced thymic cellularity and inhibition of T-cell development, as well as defects in activation-induced proliferation of mature T cells caused by an arrest at the G0/S transition (Newton et al., 1998; Walsh et al., 1998; Zhang et al., 1998; Hueber et al., 2000) . This effect did not appear to be caused by defective T-cell receptor activation, but rather by a disruption of cell cycle, as evidenced by the deregulated expression of several cell cycle proteins (Newton et al., 2001; Zhang et al., 2001) . The growth-inhibitory effect was also observed in fibroblasts expressing FADD-DN, suggesting a more The death effector domain protein family BC Barnhart et al global function for FADD in cell cycle regulation (Hueber et al., 2000) . Interestingly, the effect of FADD-DN appears to be cancer dependent since it can inhibit cell cycle progression or is even toxic in normal cells, an effect which is not observed in cancerous cells (Chinnaiyan et al., 1996a; Newton et al., 1998; Scaffidi et al., 2000; Morgan et al., 2001) . This indicates that aside from its function in apoptosis signaling, FADD may be required for normal cell proliferation and regulation of the cell cycle machinery, a function that may be lost in the process of oncogenesis. FADD's phosphorylation in a cell cycle-dependent manner offers an attractive possibility as to how FADD may function in this pathway.
For a developing tumor, FADD is a double-edged sword; loss of its function will result in increased cell survival by inhibiting death receptor-mediated apoptosis as well as synergistic effects by anticancer drugs (Sheikh et al., 1998; Micheau et al., 1999a, b) . However, FADD deficiency may also result in impaired cell cycle progression and proliferation, suggesting that a cancer cell may have to first bypass FADD's regulatory role on the cell cycle before gaining an advantage in inhibiting apoptosis. This may explain why there are relatively few reports of malignancies associated with the disruption of the FADD gene, although it has been reported in renal cell carcinoma and non-small-cell lung cancer (Uzzo et al., 2001; Shin et al., 2002a) . Cancer therapies that can distinguish between the two functions of FADD will be of interest in the future.
Caspase-8 and -10
Two caspases, caspase-8 and -10, contain DEDs (Figure 1 ). Caspases are cysteine proteases responsible for the dismantling of the cell during apoptosis. These proteins are expressed as zymogens and become active proteases only after their cleavage at specific sites within the molecule . The structure of caspases is generally conserved; they contain a prodomain at the N-terminus, and a catalytic protease domain at the C-terminus, consisting of a large and small subunit. The active caspase molecule is comprised of a heterotetramer of two of each of the large and small subunits. Caspases have been divided into two groups based on their general role in apoptosis. Effector caspases induce the bulk of the morphological changes that occur during apoptosis. These caspases have diverse cellular targets which are cleaved during apoptosis leading to these observed changes (Earnshaw et al., 1999; Stegh and Peter, 2001) . The other general class of caspases, initiator caspases, are generally responsible for the activation of the effector caspases. Initiator caspases have far fewer targets than effector caspases and, indeed, their main targets appear to be the effector caspases. Activation of the initiator caspases occurs through their oligomerization, mediated by adaptor molecules. Once this oligomerization occurs, it leads to the autoproteolytic cleavage of the initiator caspases in what has been termed the induced proximity model (Muzio et al., 1998; Salvesen and Dixit, 1999) , resulting in their activation. The initiator caspases are brought into proximity by association through protein-protein interaction domains found in both the adaptor and the caspase. Two tandem DEDs in the prodomain of caspase-8 and -10 induce the interaction of these molecules with FADD.
Recent work has begun to elucidate the mechanism of caspase-8 activation at the DISC (Chang et al., 2003) . The authors found that caspase-8 activity could first be detected in the zymogen form of the molecule upon dimerization, which occurs following recruitment to the DISC, and that only one enzyme in the homodimer is active. This activation is reminiscent of the recently described mechanism of activation of caspase-9, another initiator caspase activated by association with its adaptor, in this case Apaf-1 (Renatus et al., 2001) . Like caspase-9, caspase-8 was also found to be processed in a stepwise manner upon dimerization. The proenzyme becomes active after recruitment to the DISC (inducing dimerization), and cleaves the small subunit from the large subunit, inducing a conformational change that exposes the cleavage site between the large subunit and the prodomain. The cleavage between the large subunit and prodomain leads to the formation of the active enzyme. Interestingly, the substrate specificity changes as the enzyme becomes activated; the dimerized proform readily recognizes the cleavage site within caspase-8, but the mature enzyme poorly recognizes the proform of caspase-8 but readily cleaves and activates caspase-3. Thus, the substrate specificity appears to change as the caspase-8 zymogen becomes the active enzyme.
Both caspase-8 and -10 have been found in the CD95 DISC (Kischkel et al., 1995; Boldin et al., 1996; Muzio et al., 1996; Vincenz et al., 1997; Ng et al., 1999; Kischkel et al., 2001; Wang et al., 2001) , although the function of caspase-8 seems to be more important for apoptosis induction. Caspase-8 is more abundant and has a well-characterized substrate specificity that fits the execution of apoptosis; mice do not have a gene for caspase-10, and it has recently been shown that caspase-10 cannot functionally replace caspase-8 in the DISC (Sprick et al., 2002) . Following activation of the CD95 receptor, apoptosis can occur through one of two pathways . Type I cells produce large amounts of active caspase-8 at the DISC, and this large amount of caspase-8 can directly cleave effector caspases bypassing the mitochondrial pathway. Type II cells are dependent on mitochondrial amplification for apoptosis, as the caspase-8 produced in a type II DISC is insufficient to directly cleave the effector caspases. The small amount of caspase-8 is capable of cleaving the protein Bid, leading to the activation of the apoptogenic activity of the mitochondria, and ultimately the activation of effector caspases Luo et al., 1998) . CD95-sensitive tumor cells (as well as cells from normal tissues) have been described, which utilize one of these two pathways The role of caspase-8 in apoptosis has been well established, though evidence has recently accumulated that indicates that caspase-8 may also play a role in proliferation in some cells. A number of nonapoptotic functions of this caspase have recently been reported, including roles in cell cycle progression, T-cell activation (Algeciras-Schimnich et al., 2002) and IL-2 secretion (Chun et al., 2002) . The use of these alternative caspase pathways by tumor cells remains to be investigated.
The initiator caspases-8 and -10 are closely related and are indeed found in the same chromosomal complex, 2q33, and likely arose from a duplication event. The role of caspase-8 in death receptor-mediated apoptosis has been well established, and has been shown to be essential for signaling through this class of receptors; studies in cells deficient in caspase-8 have clearly demonstrated this essential role (Juo et al., 1998; Varfolomeev et al., 1998) . Additionally, it is well established that the evasion of apoptosis is required for the formation of a cancerous cell (Hanahan and Weinberg, 2000) . It is not surprising then that some tumors have used the deletion or inactivation of caspases to avoid the apoptotic signal. Importantly, since the activation of these initiator caspases at death receptors depends upon oligomerization and their autoproteolytic cleavage, a mutated caspase that is recruited to the receptor could act as a dominantnegative molecule, inhibiting the activation of wild-type caspase molecules. Several groups have recently described such mutations and these mutant caspase-8 molecules led to the inhibition of apoptosis in transfection studies (Mandruzzato et al., 1997; Liu et al., 2002 ). These reports demonstrate that the mutation of the caspase-8 molecule can be one step in the formation of tumors, and suggest that caspase-8 may act as a tumor suppressor, whose loss may contribute to tumor formation.
Mutations of caspase-10 also lead to its inactivation or lack of expression. Two recent studies described such mutations in non-small-lung cell cancers and nonHodgkin lymphomas (Shin et al., 2002a, b) . Multiple mutations were found in these cancers, and again, expression of a number of these mutant proteins led to a decreased apoptotic response. The mutant caspase-10 proteins also interfered with induction of apoptosis via overexpression of either CD95 or TRAIL, indicating that these proteins could act dominant negatively when expressed in tumors.
A number of recent reports have established another interesting mechanism for evasion of apoptosis in tumors involving the hypermethylation of the caspase-8 gene region and subsequent lack of caspase-8 expression. The caspase-8 gene is often silenced in neuroblastoma patients and, in patients with gene amplification of the oncogene N-myc, the bulk of the silencing is through complete gene methylation (Teitz et al., 2000) . Hypermethylation events have been described in a variety of additional tumor cells, including lung cancers , a brain tumor and a rhabdomyosarcoma cell line (Teitz et al., 2001 ), a medulloblastoma (Zuzak et al., 2002) , and in pediatric rhabdomyosarcomas, medulloblastomas, retinoblastomas and neuroblastomas, as well as in some Wilms' tumors (Harada et al., 2002) . Resistance to TRAIL-induced apoptosis in neuroblastoma cells also correlates with lack of caspase-8 expression through a methylation of the gene (Eggert et al., 2000 (Eggert et al., , 2001 . Interestingly, the methylation of the caspase-8 gene appears to be highly specific, the related caspase-10 and c-FLIP genes (both of which are part of the same gene cluster) are not hypermethylated. The mechanism for this specificity remains to be established. The loss of caspase-8 expression due to gene methylation is likely functionally relevant, as forced re-expression of caspase-8 by treating cells with demethylating agents resulted in the expression of caspase-8 mRNA and protein, and sensitization to the death receptor as well as druginduced apoptosis (Fulda et al., 2001) . Since the methylation and silencing of caspase-8 appear to be a widespread phenomenon, and because re-expression of the caspase-8 gene has been shown to sensitize cells to apoptosis, this strategy may be useful in the treatment of cancers. Treatment with demethylating agents followed by chemotherapy may allow induction of apoptosis of tumor cells, which have silenced expression of caspase-8.
Several chemotherapeutic drugs have been shown to activate caspase-8, though the exact pathway and order of this activation is a matter of some controversy. A number of studies have shown that treatment with chemotherapeutic drugs activate death receptors, thereby activating the caspase-8 pathway, and ultimately inducing cell death. Some drugs have also been shown to activate caspase-8 independently of death receptors, and treatment of cells with caspase-8 inhibitors blocked the apoptosis induced by these drugs (reviewed in Kim et al., 2001; Petak et al., 2001) . Chemotherapeutic drugs also sensitize cells to death receptor-mediated apoptosis in several studies, while others found the activation of caspase-8 to be downstream in the activation of cell death and likely a byproduct of the activation of other caspases (Kaufmann and Earnshaw, 2000) . Since caspase-8 is an initiator caspase with few substrates, the activation of this caspase downstream of other effector caspases implies that it is not intimately involved in the apoptotic program under these circumstances. Further studies will elucidate the role of caspase-8 in drug-induced apoptosis, and may result in therapies that sensitize certain tumors to caspase-8-mediated cell death.
c-FLIP
FLICE-like inhibitory proteins (FLIPs) are similar in structure to caspase-8 (FLICE is an old acronym for caspase-8 (Muzio et al., 1996) ). The first FLIPs that were identified were of viral origin, expressed by g-herpes viruses, and were shown to be capable of blocking CD95-mediated apoptosis through association with the receptor in the DISC (Bertin et al., 1997; Hu et al., 1997a; Thome et al., 1997) . vFLIPs generally contain two tandem DEDs, which are highly homologous to the N-terminus of caspase-8 . Database searches quickly identified cellular homologues of v-FLIPs (Goltsev et al., 1997; Han et al., 1997; Hu et al., 1997b; Inohara et al., 1997; Irmler et al., 1997; Shu et al., 1997; Srinivasula et al., 1997) , termed c-FLIP S (short) and c-FLIP L (long). c-FLIP S contains only the tandem DEDs and is quite similar to v-FLIP. c-FLIP L contains not only the tandem DEDs, but also a protease-like domain, homologous to caspase-8, in which several amino acids important for protease activity are mutated, including the active site cysteine (Figure 1 ). Both splice forms of c-FLIP are recruited to the CD95 DISC, where they are believed to heterodimerize with caspase-8 (Scaffidi et al., 1999) .
Mice deficient in c-FLIP (which lack both c-FLIP L and c-FLIP S ) were recently generated. Embryonic fibroblasts (MEFs) derived from the mice (through an in vitro selection process for cell growth) were shown to be more sensitive to CD95-induced apoptosis than the wild-type MEFs. However, inconsistent with these results, c-FLIP À/À mice showed developmental defects that strikingly resembled those of caspase-8 À/À or FADD À/À mice (Varfolomeev et al., 1998; Yeh et al., 1998; Zhang et al., 1998; Yeh et al., 2000) . All these mice died between E10.5 and E11.5 with a failure in heart formation and extreme hemorrhage, suggesting a function of c-FLIP L that is similar to caspase-8 and FADD. Furthermore, transient overexpression of c-FLIP L could induce as well as inhibit apoptosis, and this proapoptotic function required the c-FLIP L protease-like domain (Goltsev et al., 1997; Han et al., 1997; Inohara et al., 1997; Shu et al., 1997) . The inhibition of apoptosis by c-FLIP has been shown to be through its recruitment to and cleavage in the DISC, but since c-FLIP L is not an active protease, the cleavage is not reciprocated, resulting in the generation of two p10 subunits (one from caspase-8, the other from c-FLIP L ) followed by no further cleavage and, therefore, production of an inactive caspase-8 molecule (Krueger et al., 2001b) . c-FLIP L was shown to be downregulated in T cells following treatment of IL-2, and was suggested to be responsible for the CD95 apoptosis sensitivity of longterm-activated peripheral T cells (Refaeli et al., 1998; Algeciras-Schimnich et al., 1999) . In contrast, we found no correlation between CD95 apoptosis sensitivity and expression levels of c-FLIP L in activated peripheral T cells (Scaffidi et al., 1999) . In fact, we and others recently showed that c-FLIP L , depending on its expression level, can either activate caspase-8/-10 in the DISC (at low concentrations) or block it (at high concentrations) (Chang et al., 2002; Micheau et al., 2002) . Therefore, even an increase of c-FLIP L expression does not necessarily result in cells that are more resistant to CD95-mediated apoptosis. Furthermore, it was recently reported that c-FLIP L does not inhibit antigen-induced cell death of T cells when expressed as a transgene in mice (Lens et al., 2002) . The situation is different for c-FLIP S , which seems to have only an antiapoptotic activity similar to the v-FLIP proteins. Both restimulated and costimulated T cells were shown to specifically upregulate c-FLIP S (Kirchhoff et al., 2000a, b) . In contrast to T cells, in B cells the role of c-FLIP L as an antiapoptotic protein seems well supported (Wang et al., 2000; Hennino et al., 2001) .
Recently, c-FLIP has been implicated in signaling alternative pathways, linking the CD95 receptor to the NF-kB, JNK and MAPK pathways. Several studies have shown that c-FLIP is involved in the transmission of the NF-kB pathway by association with TRAF2 (Hu et al., 2000; Kataoka et al., 2000) . One study found that c-FLIP recruited not only TRAF1 and 2, but also RIP and Raf-1 in addition, which activated the extracellular signal-regulated kinase (Erk) pathway (Kataoka et al., 2000) . These studies link the CD95 signaling pathway to survival pathways in addition to its well-known role in apoptosis. These studies raise the interesting possibility that CD95 may be induced to signal pathways that are distinct from those leading to the apoptosis of the cell through c-FLIP. The physiological role of CD95 in these pathways is by no means clear, however, and requires more study to determine its significance.
Unlike caspase-8 or FADD, the expression of c-FLIP L appears to be highly regulated, for example, by the mitogen-activated protein kinase pathway and the NF-kB pathway (Kreuz et al., 2001; Micheau et al., 2001) . Upregulation of c-FLIP L was also reported in many tumors, and these tumors may escape apoptosis induced through death receptors (Irmler et al., 1997; Griffith et al., 1998; Irisarri et al., 2000; Bullani et al., 2001; Olsson et al., 2001; Panka et al., 2001; . Consequently, expression of c-FLIP L as a transgene in mice results in tumor formation (Djerbi et al., 1999; Medema et al., 1999) . c-FLIP has a short half-life and therefore downregulation of c-FLIP can be induced by many different means such as metabolic inhibitors, which results in the sensitization of tumors to apoptosis (Fulda et al., 2000; Kinoshita et al., 2000; Chatterjee et al., 2001; Hyer et al., 2002; Kim et al., 2002; Siegmund et al., 2002) . This is most relevant for the treatment of tumors with TRAIL, a member of the TNF superfamily of ligands that is highly cytotoxic to tumor cells (Held and Schulze-Osthoff, 2001 ). However, many tumor cells are also resistant to TRAIL but can be sensitized by downregulating c-FLIP (Fulda et al., 2002; Kelly et al., 2002; MacFarlane et al., 2002) . The expression level of c-FLIP L is thus a focal point for apoptosis regulation, and it can not only determine whether the apoptosis pathway is turned on or off but also seems to allow the cell to switch between apoptosis and survival pathways. c-FLIP L therefore represents an attractive target for therapeutic intervention with death receptor signaling, especially in combination with TRAIL in cancer treatment.
DEDD and DEDD2
DEDD (death effector domain containing DNA binding) is a ubiquitous and abundant protein that delineates a new family of DED proteins (Figure 1) (Leo et al., 1998; Stegh et al., 1998; Schickling et al., 2001; Lee et al., 2002) . Despite homology of the DED in DEDD to the corresponding regions in FADD and caspase-8, DEDD possesses several unique properties. At the level of the primary protein structure, human DEDD shares 498% sequence identity with murine DEDD, a much greater level of conservation than any other DED-containing protein. DEDD exhibits DNA-binding capacities, localizes to nucleoli in overexpression, and activates apoptosis though caspase-6 cleavage dependent upon nuclear localization (Stegh et al., 1998; Schickling et al., 2001) . In the nucleus, DEDD associates with a recently described molecule called DEDAF (DED-associated factor) and DEDD-induced apoptosis is potentiated by coexpression of DEDAF (Zheng et al., 2001) . Additionally, overexpression studies demonstrate that nuclear DEDD blocks RNA polymerase I-dependent transcription in the nucleoli . Recently, a DEDD homologue, called DEDD2/ FLAME-3, has been identified and shares 48.5% sequence identity with DEDD (Lee et al., 2002; Roth et al., 2002; Zhan et al., 2002) . Like DEDD, DEDD2 is ubiquitously expressed and localizes to the nucleoli in overexpression. DEDD2 overexpression studies also noted an interaction with c-FLIP (Roth et al., 2002) and a role for DEDD and DEDD2 in polymerase IIdependent transcription repression through TFIIIC102 interaction (Zhan et al., 2002) . Though previous reports have detected minimal caspase-8 binding to DEDD, one recent report indicates stronger affinities of caspase-8 and -10 to DEDD and DEDD2 in coexpression systems, as well as an interaction between DEDD and DEDD2 (Alcivar et al., 2003) .
Contrary to overexpression data, the majority of endogenous DEDD resides in the cytoplasm as non, mono and diubiquitinated forms (Lee et al., 2002) . Following apoptosis induction, DEDD mono and/or diubiquitination increases and forms filamentous structures that colocalize with the keratin 8/18 (K8/18) intermediate filament network in simple epithelial cells. Though such filamentous structures are reminiscent of death effector filaments (DEFs) found in overexpression studies with caspase-8 and FADD (Siegel et al., 1998) , DEDD filaments exist only in endogenous circumstances and are morphologically distinct. However, the proposed function of DEFs in caspase recruitment to substrates may be shared by DEDD filaments. In HeLa cells, endogenous diubiquitinated DEDD coimmunoprecipitates with K18 and caspase-3, suggesting that DEDD may function as an adaptor between effector caspases and specific substrates. This activity likely depends on ubiquitination and/or nuclear localization of DEDD.
The combination of overexpression and endogenous work depicts a strong dual nature of DEDD. As predicted from the extremely high sequence conservation and confirmed by RNAi downregulation, DEDD is important for cell survival. However, in apoptosis, DEDD not only activates caspase-6 resulting in lamin cleavage in the nucleus, but DEDD may also play a role in mediating caspase-3 cleavage of K18. This functional duality parallels the ability of DEDD to reside in dual subcellular compartments, as well as to exist as nonubiquitinated and ubiquitinated species.
PEA-15/PED
PEA-15/PED (phosphoprotein enriched in astrocytes of 15 kDa/phosphoprotein enriched in diabetes) is an additional DED family member with pleiotropic effects (Figure 1) . Structurally, PEA-15 is a small protein consisting of an N-terminal DED and two phosphorylation sites for PKC (Ser104) and calcium calmodulin kinase II (Ser116) (Araujo et al., 1993; Kubes et al., 1998) . The phosphorylation states of PEA-15 appear to specifically alter the functional role of PEA-15 as well as the localization of the protein, such that the doubly phosphorylated form is localized to the membrane (Danziger et al., 1995) . In addition, the TRAIL receptor DISC contains the doubly phosphorylated PEA-15 species in TRAIL-resistant gliomas (Xiao et al., 2002) .
PEA-15 functions as an antiapoptotic DED protein in multiple signaling cascades. In TNF a-, CD95-and TRAIL-mediated pathways, PEA-15 acts in a receptorproximal manner to bind and disrupt FADD and caspase-8 interactions dependent upon an intact DED (Condorelli et al., 1999; Estelles et al., 1999; Kitsberg et al., 1999; Hao et al., 2001; Xiao et al., 2002) . In the MAP kinase signaling pathways, PEA-15 binds and activates ERK in a Ras-dependent manner, as well as controls JNK and p38 activities in overexpression systems (Ramos et al., 2000; Condorelli et al., 2002; Hill et al., 2002) . However, the exact mechanism by which PEA-15 mediates ERK activation is complicated by the ability of transfected PEA-15 to export ERK from the nucleus to the cytoplasm (Formstecher et al., 2001) . Apart from apoptosis, PEA-15 also inhibits insulin-mediated glucose transport in transfected muscle cells and a high level of PEA-15 mRNA expression has been correlated to type II diabetes mellitus (Condorelli et al., 1998) . Finally, a recent report indicates that the DED of PEA-15 interacts with and likely stabilizes phospholipase D in a manner reminiscent of a chaperone (Zhang et al., 2000a) . Interestingly, the PEA-15/ ERK and PEA-15/PLD interaction depends on an intact DED, illustrating a versatility of this domain beyond associating with other classical apoptotic molecules.
With the diversity and quantity of signaling cascades regulated by PEA-15, it is no surprise that PEA-15 may play an important role in oncogenesis. PEA-15 contains the mammary transforming (MAT1) proto-oncogene in the 3 0 untranslated region of the 2.5 kb splice form (Bera et al., 1994; Tsukamoto et al., 2000) . The MAT1-containing PEA-15 mRNA is expressed weakly during certain physiological circumstances, but becomes strongly expressed in murine mammary tumors and squamous carcinoma cells (Dong et al., 2001) . Similarly, enhanced expression of PEA-15 has also been found in human tumors such as TRAIL-resistant gliomas (Hao et al., 2001 ).
Proteins with a DED-related domain

NDED/SCC-S2/GG2_1
NF-kB-inducible death effector domain-containing protein (NDED/GG2_1/SCC-S2) represents a unique member of the antiapoptotic DED proteins (Figure 1 ). NDED is a 188 amino-acid protein that contains an Nterminal DED, a putative protein kinase C phosphorylation site and a putative casein kinase II phosphorylation site (Kumar et al., 2000) . Though originally identified by a differential display screen in TNF-astimulated vascular endothelial cells (Horrevoets et al., 1999) , NDED mRNA is expressed in all normal human tissues and all cancerous cell lines tested with a relatively higher expression in lymphoid cells (Kumar et al., 2000) . Interestingly, cells in multiple sclerotic and atherosclerotic lesions also exhibit higher levels of NDED expression. In all cell lines tested, NDED mRNA increase occurs within 1 h and peaks around 3-4 h following cytokine treatment (You et al., 2001) . Functionally, NDED stable transfectants exhibit protection from apoptosis following TNF-a stimulation when compared to vector cells by inhibition of caspase-8 activity but not caspase-8 processing. In addition, the antiapoptotic effects of NDED are specific to caspase-8-mediated cell death and do not play a significant role in etoposideinduced, caspase-8-independent cell death.
In light of the work by You and colleagues, the mechanism of NDED apoptosis inhibition appears to depend on a direct or indirect inactivation of cleaved caspase-8. The inability to coimmunoprecipitate NDED in combination with caspase-8 or FADD supports the likelihood that NDED cooperates with another novel molecule that may act similarly to the IAP family of proteins, but is specific to extrinsic death signals. Considering the importance of NDED in preventing TNF-a-induced cell death in physiological and pathological circumstances, both NDED and NDED interacting proteins are of great interest as direct targets in future cancer therapies.
BAR
The bifunctional apoptosis regulator (BAR) protein was cloned from a yeast-based screen that selected for proteins that inhibited Bax-induced cell death (Zhang et al., 2000b) . This protein was shown to mediate an interaction between caspase-8 and Bcl-2 in overexpression studies. This interaction is interesting because caspase-8 and Bcl-2 have been shown not to interact directly. Overexpression of BAR also suppressed apoptosis in 293 cells. Our laboratory has begun to explain the mechanism of this apoptosis inhibition, which involves the sequestration and inactivation of active caspase-8 on the surface of mitochondria in the breast carcinoma cell line MCF7. This inhibition involves the interaction between Bcl-x L and BAR . This inactivation occurred following ligation of the CD95 receptor and production of caspase-8, but before the cleavage of any other caspase-8 target proteins.
Further studies will determine if this inactivation could be reversed by disruption of the interaction between these molecules, thus leading to the reactivation of caspase-8 and ultimately cell death.
BAP31
BAP31 was originally cloned as a protein associated with surface IgD (Adachi et al., 1996) . BAP31 was later shown to associate with Bcl-2/Bcl-x L and procaspase-8 in the endoplasmic reticulum (ER) (Ng et al., 1997) . When associated with these two proteins, BAP31 inhibits cell death induced by adenovirus E1A proteins. BAP31 is cleaved in the absence of high Bcl-2/x L expression and yields a highly toxic molecule, and expression of a caspase-resistant BAP31 mutant inhibits CD95-mediated apoptosis (Nguyen et al., 2000) . The complex formed by BAP31, Bcl-2/x L and procaspase-8 may result in an inhibition of activation of caspases at the ER. Disruption of this complex may allow cleavage of BAP31 and lead to apoptosis in certain cancer cells, but this remains to be tested. An alternative splice form of caspase-8, termed procaspase-8 L , was found to selectively bind to the complex of BAP31 and Bcl-2 at the ER (Breckenridge et al., 2002) . This form of caspase-8 was not detected in the DISC and was activated in response to E1A signaling, suggesting that procaspase-8 L is recruited and activated at this organelle and not at the cell surface in association with death receptors, as are the other isoforms of caspase-8. The physiological role of this alternative caspase-8 activation pathway remains to be established.
HIP-1 and HIPPI
Huntingtin interacting protein-1 (HIP-1) was identified through its interaction with huntingtin (Htt), a protein that in its mutated form with expanded polyglutamine repeats forms protein aggregates in the brain of Huntington's disease (HD) patients (Hackam et al., 2000) . HIP-1 was found to contain a pseudo DED (pDED) by using sequence alignments (Figure 2 ). Similar to all other DED proteins, overexpression of HIP-1 induces apoptosis in certain cells. This form of apoptosis depends on HIP-1's DED, and was characterized by activation of caspase-3 which was reduced when wild-type but not mutated Htt was coexpressed, suggesting that HIP-1 cooperates with Htt in the pathogenesis of the disease. To screen for HIP-1 pDED interacting proteins, a yeast-two-hybrid screen was performed, identifying a protein of 419 amino acids named HIPPI (for HIP-1 protein interactor) (Gervais et al., 2002) . Subsequent experiments revealed that HIP-1-induced apoptosis depends on the presence of HIPPI. A HIP-1/HIPPI heterodimer is formed only in disease tissue that recruits and activates caspase-8. The contribution of this new receptor-independent pathway in caspase activation resulting in the progression of HD is not clear yet.
FLASH
FLICE-associated huge protein (FLASH) was suggested to associate with the CD95 receptor (Imai et al., 1999) , and was shown to be recruited to the DISC of the activated receptor and to actually be required for the activation of caspase-8 at the DISC. A DED recruitment domain (DRD) was identified in FLASH, but its homology with a DED is very weak (Koonin et al., 1999) and its function is unclear at present. Recently, it was shown that FLASH regulates TRAF2-mediated activation of NF-kB (Choi et al., 2001 ).
Structure and function of DEDs
A classification of DEDs into two classes depending on the amino-acid composition of a-helix 3 has been recently proposed (Kaufmann et al., 2002) . However, in Figure 2 , we aligned all known human DED proteins to demonstrate the level of conservation among these DED proteins. The conserved anchor residues of the DED motif are readily apparent. We did not find a significant homology with these key residues, and therefore failed to align four of the published DEDlike domain containing proteins, NDED (You et al., 2001) , HIPPI (Gervais et al., 2002) , BAP31 (Ng et al., 1997) and FLASH (Imai et al., 1999) . These proteins had been reported to contain either a pseudo DED, a DED-like domain or a DRD. Recent data also challenge the simple dogma that one domain with a DED fold interacts with only one domain of the same class. It has been suggested that the FADD DED could interact simultaneously with the DEDs of caspase-8 and c-FLIP, allowing the formation of a ternary complex (Kaufmann et al., 2002; M Werner, personal communication) . This model would explain how c-FLIP can regulate the caspase-8 activity in the DISC both positively and negatively. Another interesting finding comes from structural and mutagenesis analyses of FADD. It has recently been shown that for high-affinity binding between FADD and CD95, FADD must interact with the receptor with both its DD and its DED M Werner, personal communication) .
Despite the more detailed knowledge on the number and functions of DED-containing proteins, the number of proteins that contain a clearly defined DED has remained relatively small. In contrast to the numerous members of the DD, CARD, or pyrin domain protein families, there are only seven proteins that we consider to have true DED domains (Figure 1 ). All of these proteins have been shown to function at crucial steps during apoptosis signaling. This high level of specificity together with the restricted number of proteins gives rise to the hope that it will be possible to therapeutically interfere with interactions regulated by DED proteins in pathological situations with dysregulated apoptosis. Figure 2 Alignment of all human DED-containing proteins. Positions of the six FADD -helices are shown. Identical residues are shaded in red when more than 50% of the sequences match the consensus. Conserved residues are shown in pink when more than 50% of the sequences matched the consensus. Accession numbers used to do the alignment: FADD: NM_003824; caspase-8: NM_001228; caspase-10: NM_001230; c-FLIP: NP_003870; DEDD: NP_127491; DEDD2: NM_133328; NDED: AF070671; BAP31: NM_005745; BAR: AF173003; HIP-1: AF365404; HIPPI: AF245220; FLASH: AF154415. The sequences of the putative DED-like domains in BAP31, HIPPI, FLASH and NDED could not be aligned due to insufficient similarity with the consensus. Alignment was done with the help of Megalign (Lasergene)
